Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cynata Therapeutics Limited ( (AU:CYP) ) has issued an announcement.
Cynata Therapeutics Limited has announced the cessation of three tranches of listed options on the ASX, each with different exercise prices of $0.30, $0.40 and $0.50, after a total of 3,000,000 options expired unexercised on 2 April 2026. The expiry of these options without conversion reduces the company’s pool of potential dilutive securities, slightly simplifying its capital structure and clarifying the current fully paid equity base for existing shareholders.
The most recent analyst rating on (AU:CYP) stock is a Hold with a A$0.29 price target. To see the full list of analyst forecasts on Cynata Therapeutics Limited stock, see the AU:CYP Stock Forecast page.
More about Cynata Therapeutics Limited
Cynata Therapeutics Limited is a biotechnology company listed on the ASX under the code CYP. The company operates in the life sciences sector, focusing on the development and commercialisation of therapeutic products, with its capital structure including various classes of options and convertible securities traded on the Australian market.
YTD Price Performance: -14.49%
Average Trading Volume: 247,441
Technical Sentiment Signal: Buy
Current Market Cap: A$70.05M
For detailed information about CYP stock, go to TipRanks’ Stock Analysis page.